Compare Baxter International Inc (BAX) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Veritone Inc — how do they compare? Baxter International Inc trades at $26.74 (market cap $14.27B), while Veritone Inc trades at $1.47 (market cap $138.04M). The key difference: Baxter International Inc is far larger — about 103.4× Veritone Inc's market cap, and Baxter International Inc pays a 0.14% dividend while Veritone Inc pays none. Which is the better fit depends on your goals.
| BAX | VERI | |
|---|---|---|
Market Cap | $14.27B | $138.04M |
Sector | Health | Technology |
52-Week High | $28.35 | $8.39 |
52-Week Low | $15.80 | $1.00 |
Enterprise Value | $21.79B | $170.07M |
Dividend Yield | 0.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International Inc. (BAX) trades at $27.78, up 0.83% today, with a bullish technical outlook supported by moving averages. Recent Q2 2026 earnings beat estimates with EPS of $0.56 versus $0.37 expected, and revenue guidance was raised, signaling operational improvement. However, the company posted a net loss of -$957 million in 2025, with negative profit margins and high P/E of 87.85, reflecting valuation concerns amid turnaround efforts.
The stock shows potential from earnings momentum and cost initiatives, but high debt and inconsistent profitability pose risks. Analyst consensus is mixed with a $25.43 price target below current levels, suggesting cautious optimism. Investors should weigh recent beats against structural challenges in the medtech sector.
Veritone (VERI) trades at $1.46, up 1.39% today, with a bullish technical signal from moving averages despite overbought RSI readings. The company reported a net loss of $111.73M on $92.19M revenue in 2025, with negative profit margins and ROE. Recent news highlights partnerships in AI solutions, but a securities class action lawsuit deadline passed in July 2026.
Outlook remains challenged by persistent losses and high cash burn, offset by analyst optimism with 46% buy ratings. Key risks include the class action, profitability timeline, and competitive AI market. The stock's low price near support levels suggests high volatility potential amid mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
